332 related articles for article (PubMed ID: 12060617)
1. A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphoma.
Schnell R; Staak O; Borchmann P; Schwartz C; Matthey B; Hansen H; Schindler J; Ghetie V; Vitetta ES; Diehl V; Engert A
Clin Cancer Res; 2002 Jun; 8(6):1779-86. PubMed ID: 12060617
[TBL] [Abstract][Full Text] [Related]
2. Clinical evaluation of ricin A-chain immunotoxins in patients with Hodgkin's lymphoma.
Schnell R; Borchmann P; Staak JO; Schindler J; Ghetie V; Vitetta ES; Engert A
Ann Oncol; 2003 May; 14(5):729-36. PubMed ID: 12702527
[TBL] [Abstract][Full Text] [Related]
3. A phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin's lymphoma.
Engert A; Diehl V; Schnell R; Radszuhn A; Hatwig MT; Drillich S; Schön G; Bohlen H; Tesch H; Hansmann ML; Barth S; Schindler J; Ghetie V; Uhr J; Vitetta E
Blood; 1997 Jan; 89(2):403-10. PubMed ID: 9002941
[TBL] [Abstract][Full Text] [Related]
4. Clinical trials with an anti-CD25 ricin A-chain experimental and immunotoxin (RFT5-SMPT-dgA) in Hodgkin's lymphoma.
Schnell R; Vitetta E; Schindler J; Barth S; Winkler U; Borchmann P; Hansmann ML; Diehl V; Ghetie V; Engert A
Leuk Lymphoma; 1998 Aug; 30(5-6):525-37. PubMed ID: 9711915
[TBL] [Abstract][Full Text] [Related]
5. Antitumor effects of ricin A chain immunotoxins prepared from intact antibodies and Fab' fragments on solid human Hodgkin's disease tumors in mice.
Engert A; Martin G; Pfreundschuh M; Amlot P; Hsu SM; Diehl V; Thorpe P
Cancer Res; 1990 May; 50(10):2929-35. PubMed ID: 1692251
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of an anti-CD19 deglycosylated ricin A chain immunotoxin in non-Hodgkin's lymphoma: effect of an intensive schedule of administration.
Conry RM; Khazaeli MB; Saleh MN; Ghetie V; Vitetta ES; Liu T; LoBuglio AF
J Immunother Emphasis Tumor Immunol; 1995 Nov; 18(4):231-41. PubMed ID: 8680651
[TBL] [Abstract][Full Text] [Related]
7. Treatment of refractory Hodgkin's lymphoma patients with an anti-CD25 ricin A-chain immunotoxin.
Schnell R; Vitetta E; Schindler J; Borchmann P; Barth S; Ghetie V; Hell K; Drillich S; Diehl V; Engert A
Leukemia; 2000 Jan; 14(1):129-35. PubMed ID: 10637488
[TBL] [Abstract][Full Text] [Related]
8. Development of new ricin A-chain immunotoxins with potent anti-tumor effects against human Hodgkin cells in vitro and disseminated Hodgkin tumors in SCID mice using high-affinity monoclonal antibodies directed against the CD30 antigen.
Schnell R; Linnartz C; Katouzi AA; Schön G; Bohlen H; Horn-Lohrens O; Parwaresch RM; Lange H; Diehl V; Lemke H
Int J Cancer; 1995 Oct; 63(2):238-44. PubMed ID: 7591211
[TBL] [Abstract][Full Text] [Related]
9. Phase II clinical trial of bolus infusion anti-B4 blocked ricin immunoconjugate in patients with relapsed B-cell non-Hodgkin's lymphoma.
Multani PS; O'Day S; Nadler LM; Grossbard ML
Clin Cancer Res; 1998 Nov; 4(11):2599-604. PubMed ID: 9829722
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of ricin A chain-containing immunotoxins directed against the CD30 antigen as potential reagents for the treatment of Hodgkin's disease.
Engert A; Burrows F; Jung W; Tazzari PL; Stein H; Pfreundschuh M; Diehl V; Thorpe P
Cancer Res; 1990 Jan; 50(1):84-8. PubMed ID: 2152774
[TBL] [Abstract][Full Text] [Related]
11. Phase I immunotoxin trial in patients with B-cell lymphoma.
Vitetta ES; Stone M; Amlot P; Fay J; May R; Till M; Newman J; Clark P; Collins R; Cunningham D
Cancer Res; 1991 Aug; 51(15):4052-8. PubMed ID: 1855219
[TBL] [Abstract][Full Text] [Related]
12. A Phase II study of adjuvant therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with relapsed B-cell non-Hodgkin's lymphoma.
Grossbard ML; Multani PS; Freedman AS; O'Day S; Gribben JG; Rhuda C; Neuberg D; Nadler LM
Clin Cancer Res; 1999 Sep; 5(9):2392-8. PubMed ID: 10499609
[TBL] [Abstract][Full Text] [Related]
13. [New perspectives in oncology: is selective destruction of tumor cells with immunotoxins in Hodgkin's disease an additional therapeutic alternative?].
Engert A; Gottstein C; Winkler U; Schön G; Amlot P; Thorpe P; Diehl V
Med Klin (Munich); 1992 Oct; 87(10):503-9. PubMed ID: 1461215
[TBL] [Abstract][Full Text] [Related]
14. The toxicity of deglycosylated ricin A chain-containing immunotoxins in patients with non-Hodgkin's lymphoma is exacerbated by prior radiotherapy: a retrospective analysis of patients in five clinical trials.
Schindler J; Sausville E; Messmann R; Uhr JW; Vitetta ES
Clin Cancer Res; 2001 Feb; 7(2):255-8. PubMed ID: 11234876
[TBL] [Abstract][Full Text] [Related]
15. The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease.
Wahl AF; Klussman K; Thompson JD; Chen JH; Francisco LV; Risdon G; Chace DF; Siegall CB; Francisco JA
Cancer Res; 2002 Jul; 62(13):3736-42. PubMed ID: 12097283
[TBL] [Abstract][Full Text] [Related]
16. Single-dose murine monoclonal antibody ricin A chain immunotoxin in the treatment of metastatic melanoma: a phase I trial.
Gonzalez R; Salem P; Bunn PA; Zukiwski AA; Lamb R; Benjamin RS; Spitler L; Wedel N; Robinson WA
Mol Biother; 1991 Dec; 3(4):192-6. PubMed ID: 1768370
[TBL] [Abstract][Full Text] [Related]
17. Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody.
Schnell R; Dietlein M; Staak JO; Borchmann P; Schomaecker K; Fischer T; Eschner W; Hansen H; Morschhauser F; Schicha H; Diehl V; Raubitschek A; Engert A
J Clin Oncol; 2005 Jul; 23(21):4669-78. PubMed ID: 16034043
[TBL] [Abstract][Full Text] [Related]
18. An anti-CD30 single-chain Fv selected by phage display and fused to Pseudomonas exotoxin A (Ki-4(scFv)-ETA') is a potent immunotoxin against a Hodgkin-derived cell line.
Klimka A; Barth S; Matthey B; Roovers RC; Lemke H; Hansen H; Arends JW; Diehl V; Hoogenboom HR; Engert A
Br J Cancer; 1999 Jun; 80(8):1214-22. PubMed ID: 10376974
[TBL] [Abstract][Full Text] [Related]
19. A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma.
Messmann RA; Vitetta ES; Headlee D; Senderowicz AM; Figg WD; Schindler J; Michiel DF; Creekmore S; Steinberg SM; Kohler D; Jaffe ES; Stetler-Stevenson M; Chen H; Ghetie V; Sausville EA
Clin Cancer Res; 2000 Apr; 6(4):1302-13. PubMed ID: 10778955
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of involved-field radiotherapy preceding autologous stem cell transplantation for patients with high-risk lymphoma or Hodgkin's disease.
Dawson LA; Saito NG; Ratanatharathorn V; Uberti JP; Adams PT; Ayash LJ; Reynolds CM; Silver SM; Schipper MJ; Lichter AS; Eisbruch A
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):208-18. PubMed ID: 15093918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]